SK Biopharm, Stock Price +2.59% at This Hour... 1,995,881 Shares Net Bought by Individuals in the Last 5 Days
As of 10:32 AM on the 5th, SK Biopharm is trading at 158,500 KRW, up 2.59% from the previous day. The trading volume is 849,332 shares, which is 25.71% of the previous day's volume.
On January 4th, researcher Han Byunghwa of Eugene Investment & Securities stated, "The global market expansion of Cenobamate is underway. As the indication of the main drug Cenobamate expands from partial seizures to generalized seizures in the U.S. market, sales are expected to surge. Starting in 2025, sales of Carisbamate, a treatment for Lennox-Gastaut syndrome, will also begin, which will further increase profit growth. If early-stage clinical drugs such as Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741, which are likely to be commercialized, receive approval, earnings estimates will be raised even higher." He set the target price for SK Biopharm at 150,000 KRW.
Over the past five days, individual investors have net purchased 1,995,881 shares of SK Biopharm, while foreigners and institutions have net purchased 38,195 shares and net sold 1,975,235 shares, respectively.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- KDB and Others Arrange 2.5 Trillion Won Financing for Doosan's Acquisition of SK Siltron
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
